Maxigen Biotech Inc

Maxigen Biotech Inc

1783 · TW · Healthcare / Medical Instruments & Supplies

36.00TWD+0.20 (+0.56%)

Price History

Full chart

Market Stats

Previous Close35.80
Open36.10
Day Range35.45 – 36.40
52-Week Range36.10 – 48.30
Volume60.22K
Market Cap3.34B
P/E (TTM)11.53
Forward P/E0.00
EPS3.23
Dividend Yield5.35%
Beta0.39
50-Day Avg38.98
200-Day Avg41.23

About

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMs. Ching-Ting Chen
  • Employees0
  • HeadquartersNo.88, Keji 1st Rd., Taoyuan City, Taiwan, 333, Taiwan
  • Websitehttps://mbi-bio.com

Leadership

  • Ms. Ching-Ting ChenGM & Representative Director
  • Mr. Ruei Yi WuFinancial Officer & Accounting Officer
  • Mr. Hao-Jun WangSupervisor of the Preci-sion Manufacturing Center
  • Ms. Karen LeeSenior Manager of Administration

Financials

Income Statement

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue180.60M172.44M178.88M222.00M232.95M245.69M261.47M336.39M427.56M427.68M452.20M457.69M511.98M604.43M622.12M680.65M811.56M
Growth (%)--4.52%+3.73%+24.11%+4.93%+5.47%+6.42%+28.65%+27.10%+0.03%+5.73%+1.21%+11.86%+18.06%+2.93%+9.41%+19.23%
Cost of Revenue101.58M107.94M127.90M120.43M125.74M149.62M169.94M201.47M267.28M245.11M234.93M243.17M250.95M230.44M198.02M197.33M247.84M
Gross Profit79.03M64.50M50.98M101.56M107.21M96.07M91.53M134.92M160.28M182.57M217.27M214.52M261.03M373.99M424.09M483.32M563.72M
Gross Margin43.76%37.40%28.50%45.75%46.02%39.10%35.01%40.11%37.49%42.69%48.05%46.87%50.98%61.88%68.17%71.01%69.46%
Operating Expense71.72M95.43M92.61M112.24M110.77M124.67M152.06M146.23M139.24M136.44M141.18M137.63M160.34M203.43M274.24M288.95M302.68M
Operating Income7.31M-30.93M-41.64M-10.67M-3.56M-28.60M-60.52M-11.31M21.05M46.13M76.09M76.89M100.69M170.56M149.85M194.38M261.04M
Operating Margin4.05%-17.94%-23.28%-4.81%-1.53%-11.64%-23.15%-3.36%4.92%10.79%16.83%16.80%19.67%28.22%24.09%28.56%32.17%
EBITDA17.68M-3.92M-20.75M11.92M3.09M-10.54M-47.61M10.94M46.55M87.54M108.69M110.08M130.53M195.40M177.09M221.40M293.18M
EBITDA Margin9.79%-2.27%-11.60%5.37%1.33%-4.29%-18.21%3.25%10.89%20.47%24.03%24.05%25.50%32.33%28.47%32.53%36.13%
Net Income12.63M-16.00M-36.07M2.76M2.58M-19.04M-62.96M-12.25M15.79M57.05M60.11M63.31M87.67M139.40M165.83M190.17M265.31M
Net Income Margin6.99%-9.28%-20.17%1.25%1.11%-7.75%-24.08%-3.64%3.69%13.34%13.29%13.83%17.12%23.06%26.66%27.94%32.69%
R&D21.33M25.10M26.33M34.41M32.41M32.80M48.74M36.26M43.31M50.67M66.86M69.15M75.68M99.63M68.59M111.83M126.05M
R&D as % of Total Revenue11.81%14.56%14.72%15.50%13.92%13.35%18.64%10.78%10.13%11.85%14.79%15.11%14.78%16.48%11.03%16.43%15.53%
Interest Expense--631.00K1.36M1.68M1.64M2.26M4.81M4.12M4.02M3.43M250.00K196.00K68.00K0043.00K
Interest Expense % of Total Revenue--0.35%0.61%0.72%0.67%0.87%1.43%0.96%0.94%0.76%0.05%0.04%0.01%0.00%0.00%0.01%

Balance Sheet

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets343.55M429.76M486.65M505.76M1.01B1.01B1.17B1.10B1.10B1.14B1.19B956.47M1.27B1.45B1.49B1.58B1.89B
Total Liabilities30.51M34.37M117.40M120.10M126.04M136.65M338.38M316.04M307.73M292.48M334.17M96.24M123.47M152.07M131.88M207.36M355.54M
Total Equity313.03M395.39M369.25M385.66M888.39M877.01M829.86M781.38M796.25M842.98M851.32M860.23M1.14B1.30B1.36B1.38B1.54B
Cash186.70M273.08M134.52M152.94M308.92M45.39M292.65M96.63M182.22M184.84M267.64M209.76M513.30M790.95M431.08M639.05M576.19M
Total Debt9.29M6.43M80.00M80.05M80.00M77.77M71.04M16.48M14.88M213.23M14.69M12.13M9.74M-50.00K-101.40M
Net Debt-177.42M-266.64M-54.52M-72.89M-228.92M32.37M-221.61M-80.15M-167.34M28.39M-252.95M-197.63M-503.56M-790.95M-431.03M-639.05M-474.79M

Cash Flow

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow19.27M-16.76M-76.64M17.53M-22.34M-14.45M-109.85M34.72M41.18M170.58M94.42M74.39M117.59M268.34M171.20M298.22M290.22M
Investing Cash Flow-14.87M7.53M-149.29M-11.28M-221.93M-252.61M137.81M-141.84M50.32M-142.30M42.62M139.13M-2.77M10.43M-490.25M-29.07M-382.99M
Financing Cash Flow84.16M95.76M86.94M12.40M497.07M3.39M219.34M-86.05M-5.28M-25.72M-54.41M-271.35M188.69M-1.05M-41.39M-59.73M30.66M
Capital Expenditure7.62M6.00M138.47M6.24M57.99M130.99M127.24M72.71M29.01M20.23M23.74M11.34M15.45M14.44M22.44M31.77M82.63M
Free Cash Flow11.65M-22.76M-215.10M11.28M-80.32M-145.44M-237.09M-37.99M12.17M150.36M70.68M63.06M102.15M253.90M148.76M266.45M207.59M
Dividends Paid------10.84M10.84M10.84M10.84M51.86M54.18M56.27M-42.35M88.96M74.43M
FCF to OCF60.48%135.79%280.67%64.37%359.61%1006.41%215.83%-109.42%29.55%88.14%74.86%84.76%86.86%94.62%86.89%89.35%71.53%
Dividend Paid to FCF-------4.57%-28.54%89.10%7.21%73.38%85.93%55.08%-28.47%33.39%35.85%

Earnings

Report DateJun 30, 2013Nov 27, 2013Feb 26, 2014May 13, 2014Aug 13, 2014Nov 14, 2014Mar 30, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016May 20, 2016Aug 12, 2016Nov 11, 2016Mar 28, 2017May 15, 2017Aug 11, 2017Nov 10, 2017Feb 28, 2018May 15, 2018Aug 13, 2018Nov 12, 2018Mar 27, 2019May 8, 2019Aug 8, 2019Nov 13, 2019Mar 31, 2020May 13, 2020Aug 9, 2020Nov 11, 2020Mar 22, 2021May 14, 2021Jul 27, 2021Nov 3, 2021Mar 21, 2022May 3, 2022Aug 3, 2022Oct 25, 2022Mar 23, 2023May 3, 2023
EPS Estimate---0.090.16-0.05-------------0.150.190.25--0.26--0.200.25----------
EPS Actual0.000.010.020.03-0.03-0.02-0.23-0.17-0.20-0.08-0.36-0.14-0.04-0.020.05-0.050.110.100.040.120.290.220.060.090.320.230.110.150.260.160.170.280.280.380.160.250.390.500.510.52
Surprise----66.67%-118.75%--560.00%-------------93.33%15.79%-76.00%---11.54%--30.00%-36.00%----------
Timing---After-hoursPre-marketPre-marketPre-market----Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap3.34B
Enterprise Value2.39B
Trailing P/E11.53
Forward P/E0.00
Price / Sales3.99
Price / Book2.19
EPS3.23
Book Value16.67
Revenue (TTM)837.44M
Gross Profit (TTM)585.43M
EBITDA291.18M
Profit Margin34.77%
Operating Margin25.69%
Return on Equity20.00%
Return on Assets8.55%
Shares Outstanding89.70M
Shares Float42.10M
Beta0.39
Dividend Yield5.35%
Dividend Rate2.00
Payout Ratio25.71%

Dividends

20211×
0.66Aug 19, 2021
20201×
0.71Aug 6, 2020
20191×
0.62Jul 24, 2019
20181×
0.14Jul 24, 2018

Stock Splits

  • Nov 11, 202211:10
  • Dec 27, 2012457:451